Clinical Trial Update: "Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating epigallocatechin gallate (EGCG) with cognitive training to modulate cognitive performance in Fragile X Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• EGCG (Epigallocatechin gallate) (Epigallocatechin gallate)

Snippet

Sponsor: Parc de Salut Mar | Conditions: Fragile X Syndrome | Phase 2 | Status: COMPLETED